National Stock Exchange of India Limited Exchange Plaza
Bandra Kurla Complex Bandra (E)
Mumbai - 400 051
NSE Symbol: WOCKPHARMA
Dear Sir/ Madam,
Sub: Appointment of Mr. Pramod Gupta as the Chief Financial Officer of the Company
Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 ('Listing Regulations') read with Schedule III of Listing Regulations, we wish to inform you that the Board of Directors of the Company, at its meeting held today, accepted the request of Mr. Deepak Madnani to relinquish his responsibilities as the Chief Financial Officer of the Company and appointed Mr. Pramod Gupta as the new Chief Financial Officer of the Company with immediate effect. Brief particulars required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Circular No.
CIR/CFD/CMD/4/2015 dated September 9, 2015 including a brief profile of Mr. Pramod Gupta is enclosed as Annexure I.
Kindly take the same on record please.
Thanking you,
for Wockhardt Limited
Debashis Dey Company Secretary
Encl: As above
Annexure I
The details required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.
Sr. No.
Particulars
Details
1
Reason for change viz. appointment, resignation, removal, death or otherwise
Appointment
2
Date of appointment/cessation (as applicable) & term of appointment
4th April, 2022
Full time employee of the Company governed by the standard terms of employment as per Company Policy.
3
Brief profile (in case of appointment);
Mr. Pramod Gupta is a seasoned business leader with over 3 decades of Finance, Supply Chain, IT and Business management experience across diverse industries in organisations such as Hindustan Unilever, DHL Express, Novartis, Microsoft, Rivigo (Logistics tech start up) and Arvind Fashions. He is a qualified Chartered Accountant.
4
Disclosure of relationships between directors (in case of appointment of a director).
Nil
Attachments
Original Link
Original Document
Permalink
Disclaimer
Wockhardt Limited published this content on 04 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 April 2022 11:46:07 UTC.
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Companyâs products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
WOCKHARDT LIMITED 
